Type I and type IV allergy to the insulin analogue detemir

Lancet

Volumn 369, Issue 9562, 2007, Pages 637-638

  Sola Gazagnes, A ^a   Pecquet, C ^b   M'Bemba, J ^a   Larger, E ^a   Slama, G ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; IMMUNOGLOBULIN E ANTIBODY; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; LATEX; MYRISTIC ACID; VIRUS PROTEIN;

ACYLATION; CELL MEMBRANE; CLINICAL FEATURE; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DRUG HYPERSENSITIVITY; ERYTHEMA; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; INJECTION SITE INFLAMMATION; INTRACUTANEOUS TEST; LETTER; LYMPHOCYTE; PRIORITY JOURNAL; TREATMENT INDICATION;

EID: 33847095051     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60301-8     Document Type: Letter

References (5)

1. Darmon P., Castera V., Koeppel M., Petitjean C., and Dutour A. Type III allergy to insulin detemir. Diabetes Care 28 (2005) 2980
2. Blumer I. Severe injection site reaction to insulin detemir. Diabetes Care 29 (2006) 946
3. Resh M. Fatty acylation of proteins: new insights into membrane targeting of myristoylated and palmitoylated proteins. Biochem Biophys Acta 1451 (1999) 1-16
4. Dea M., Hamilton-Wessler M., Ader M., et al. Albumin binding of acylated insulin (NN304) does not deter action to stimulate glucose uptake. Diabetes 51 (2002) 762-769
5. Bachrach G., Banai M., Fishman Y., and Bercovier H. Delayed-type hypersensitivity activity of the Brucella L7/L12 ribosomal protein depends on posttranslational modification. Infect Immun 65 (1997) 267-271